González-Aznar E, Otero-Alfaro O, Cabrera-Blanco O, Ramírez-Bencomo F, Fajardo-Sánchez A, Mandariote-Llanes A, Cuello-Pérez M

Language: Spanish
References: 14
Page: 64-70
PDF size: 641.70 Kb.

ABSTRACT

Neisseria meningitidis serogroups A, B, C, W, Y and X are the main responsible of meningococcal disease. Vaccines are necessary to prevent this disease. The Finlay Institute is developing polysaccharide vaccines against serogroups A, C, W, Y and X. In the development of vaccines, the identity assay is a mandatory requirement for final product release. This test is performed by Dot Blot technique using commercial polyclonal antibodies (PAb). However, the Finlay Institute has monoclonal antibodies (mAbs) against capsular polysaccharides from N. meningitidis (CPs). The objective of this work was to use these mAbs in identity tests to replace commercial PAb. The specificity of the mAbs, the cross-reactivity with other CPs and the identity of the CPs present in four multivalent polysaccharide vaccines, were evaluated. All tested mAbs showed high specificity, and no cross-reactivity was found. Also all mAbs were able to identify the presence of homologous PsC in multivalent vaccine formulations. We conclude that the mAbs obtained in our institution can be used for identity assays of vaccines.

REFERENCES

1. Ochoa RF, Sierra G, Martínez I, Cuevas I. Enfermedad meningocócica. Diagnóstico microbiológico. En: Prevención de la Enfermedad Meningocócica. La Habana: Finlay Ediciones; 2010.p.3-6.

2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27(Suppl 2):51-63.

3. WHO. Meningococcal disease in countries of the African meningitis belt, 2012 – emerging needs and future perspectives. WHO 2009. Properties 2013.Weekly Epidemiological Record 2013;88:129-36.

4. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.Vaccine 2009;27(Suppl 2):3-12.

5. Healy M, Baker C. The Future of Meningococcal Vaccines. Pediatric Infectious Disease Journal 2005;24(2):175-6.

6. Danzig L. Meningococcal Vaccines. Pediatric Infectious Disease Journal 2004;23(12):285-92.

7. CECMED. Requisitos para la liberación de lotes de vacunas. Regulación No.19-2000. La Habana: CECMED; 2000.

8. Cook MC, Bliu A, Kunkel JP. Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: optimisation of hydrolysis conditions and chromatographic methods. Vaccine 2013;31(36):3702-11.

9. Ochoa RF. Técnicas inmunoenzimáticas en el desarrollo clínico de vacunas. La Habana: Finlay Ediciones; 2013.

10. Goding JW. Monoclonal Antibodies: Principles and practice. San Diego: Academic Press; 1996.

11. Falero G, Rodríguez BL, Rodríguez I, Campos J, Ledon T, Valle E, et al. Production and characterization of monoclonal antibodies to E1 Tor toxin co-regulated pilus of Vibrio cholerae. Hybrid Hybridomics 2003;22(5):315-20.

12. Reyes F, Amin N, Otero O, Aguilar A, Cuello M, Valdés Y, et al. Four monoclonal antibodies against capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y and W135: its application in identity tests. Biologicals 2013;41(4):275-8.

13. Reyes F, Otero O, Camacho F, Amin N, Ramírez F, Valdes Y, et al. A novel monoclonal antibody to Neisseria meningitidis serogroup X capsular polysaccharide and its potential use in quantitation of meningococcal vaccines. Biologicals 2014;42(6):312-5.

14. Reyes F, Otero O, Cuello M, Amin N, García L, Cardoso D, et al. Development of four sandwich ELISAs for quantitation of capsular polysaccharides from Neisseria meningitidis serogroups A, C, W and Y in multivalent vaccines. J Immunol Methods 2014;407:58-62.